Discover the press release issued on April 16, 2025.

In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope

Following a scientific pre-launch in December 2024, our Japanese teams officially presented our antimicrobial-free solution at the annual congress of the Japanese Society of Veterinary Dermatology, held on March 8th and 9th in Tokyo. Recommended as a first-line treatment for canine acute erythemato-ceruminous otitis externa, even with microbial proliferation, our approach offers an effective and safe alternative.

●    Very strong revenues increase of 13.6% at constant exchange rates, driven by:
      ○  dynamic organic growth (+7.5%) 
      ○  strategic contribution of our acquisitions (+6.1%)

●    2024 operating income2 at an all-time high of 16.6% of revenues (16.0% excluding
      acquisitions)
      ○  up by 1.5 percentage points compared to 2023 

●    Positive trend for 2025
      ○  sales growth expected between 4% and 6% at constant exchange rates and scope
      ○  operating income relatively stable at around 16%, excluding the impact of acquisitions

Our new Veterinary HPM^® digestive support wet foods have been specially designed to meet the specific needs of dogs and cats suffering from digestive disorders. Gradually available in Europe since January, they help our companions regain a better quality of daily life and facilitate their nutritional recovery in case of convalescence.

Our endocrinology offering expands with a unique solution for treating Cushing's syndrome in dogs. Available for several months in Europe, it simplifies the daily management of this hormonal disease and improves the animal's well-being.

In January, we launched four new cattle vaccines designed to protect bovines at various stages of their growth against respiratory and reproductive challenges. This marks another milestone in our ongoing commitment to expand our offering of preventive solutions for healthier herds to veterinarians and farmers in the US.

Our teams are strengthening our swine vaccine solutions to better address the local challenges faced by professionals. Available since the end of 2024 in Germany, January 2025 in France, and soon in Austria, this new broad-spectrum vaccine allows, through the vaccination of pregnant sows, passive immunization of newborn piglets against the main pathogens responsible for neonatal diarrhea.

Our American teams have worked tirelessly alongside Emmyon, Inc. to offer an innovative ursolic acid-based solution that supports muscle health in dogs. Full details of this partnership and the resulting product can be found in the press release issued on January 07, 2025. 

Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)

Since October, our French teams have been offering Day 1, a new application that allows French veterinarians and farmers to monitor and compare colostrum quality on the farm. A valuable decision-making aid to improve herd health!

Discover the video of Habib Ramdani wishes to all Virbac teams worldwide. 

In 2024, two of our fourteen Great Place To Work^®-certified subsidiaries were recognized in the Best Workplaces^® rankings. These distinctions reflect our commitment to creating inclusive, fulfilling, and trust-based work environments.

In line with our code of conduct, the business partner charter, a revisited version of our supplier code, applies to all our business partners worldwide.

On December 2, we finalized the acquisition of Turkish company Mopsan, specialized in the distribution of petfood and companion animal health products.

Our program, already available to pet veterinarians since 2023,  will also be available to farm animal veterinarians worldwide during 2025. With Let's do it smart, we offer them concrete tools for choosing pest control solutions tailored to the real needs of each farm. This helps preserve the fragile balance between man, animal and ecosystem.

In 2024, we launched several major industrial projects at our original site in Carros. More than just a local presence, we are investing to make this site a true center of excellence and a pillar of our future growth.

After its implementation in North America in 2022, we are continuing the deployment of our industrial transformation program with the launch in France in April 2024.

From January 29 to February 9, we conducted the 2024 Great Place To Work survey among our employees.

As a result of the survey, fourteen of our subsidiaries worldwide have been certified Great Places To Work. This recognition reflects our ongoing commitment to building a corporate culture based on trust and the well-being of our employees.

Strong revenue growth as of the end of September at +12.6% and +8.6% at constant exchange rates and scope. 2024 targets maintained.

In September, nearly 40 employees from our subsidiaries, head office and our panel of experts met at the Nice Côte d'Azur University for a seminar dedicated to injectable trace mineral supplementation (ITMS). The aim: to reflect collectively on ways of making micronutrition a major Group-wide asset in our approach to livestock health.

90% of cats over the age of 10  have joint issues¹ which can lead to mobility impairment and impact their quality of life. To keep their joints healthy and improve their mobility, our teams have developed a new Movoflex formula dedicated to cats. A novel soft chew, gradually available in Europe from September 2024.

With 35 subsidiaries and 5,400 employees worldwide, mastering the codes of intercultural communication is a key challenge for our Group. To meet this need, our Human Resources team launched a pilot project in France from June to August 2024.

This September, our American teams formed a strategic alliance with the association for pet obesity prevention (APOP) to confront the growing threat of pet obesity in the United States and raise awareness of the importance of pet nutrition.

The board of directors announces a capital reduction through cancellation of treasury shares

●    Exceptional business momentum in the first half, with revenue up 16.1% at constant exchange rates

●    Strong growth in adjusted current operating income1 
      ○ +3.4 points compared with 2023 to reach a record level at 21.4% of revenue

●    2024 targets confirmed  
      ○    Revenue growth expected between 7% and 9% at constant exchange rates and scope
      ○    Adjusted current operating income1 expected to be around 16% compared with 15.1% in 2023

For several decades, we have been providing industry professionals with solutions to improve milk production. From August 12-14, our teams will be at the National Mastitis Council to present our Smart DCT tool. Its purpose? To make it easier to implement selective dry-off in herds and improve milk quality worldwide.

The quality of dogs' and cats' skin and coat is essential for their health and their bond to humans. That’s probably why, since the 80’s, veterinary dermatology has grown to be the primary reason for consultations in pets. At Virbac, we have been part of this history from the outset, working alongside the founding fathers of modern veterinary dermatology, paving the way for innovation for the well-being of our companion animals. This July, as for every edition since the first one, we are principal sponsor of the 10th World Congress of Veterinary Dermatology. 

Exceptional first-half momentum (+16.2% at constant exchange rates) driven by all regions

Sébastien Huron leaves the company, Habib Ramdani takes over while the Group recruits its next chief executive officer